Correction to: Blood Cancer Journal https://doi.org/10.1038/s41408-023-00804-y, published online 22 March 2023
In the sentence beginning ‘Patients in the MM-014 trial who received...’ in this article, the text ‘lower’ should have read ‘higher’.
Moreover, the sentence beginning ‘However, these considerations should be balanced’ should have been replaced with the following sentence.
“The benefits of increased durations of lenalidomide maintenance therapy in prolonging PFS have been seen previously.”
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Raje, N., Mateos, MV., Iida, S. et al. Correction: Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy. Blood Cancer J. 13, 104 (2023). https://doi.org/10.1038/s41408-023-00866-y
Published:
DOI: https://doi.org/10.1038/s41408-023-00866-y
